Loading...
XASXATX
Market cap20mUSD
Jan 08, Last price  
0.08AUD
1D
-1.19%
1Q
-49.70%
Jan 2017
-99.18%
IPO
-95.22%
Name

Amplia Therapeutics Ltd

Chart & Performance

D1W1MN
XASX:ATX chart
P/E
—
P/S
7.23
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
34.89%
Rev. gr., 5y
144.97%
Revenues
4m
+274.34%
0030,3092,263,3151,798,113580,29050,47434,2271,533,5211,983,3161,189,4864,452,742
Net income
-5m
L-27.86%
-3,388,460-4,495,000-5,237,000-4,943,098-7,076,319-4,297,580-1,869,958-2,219,474-2,281,153-3,644,217-6,242,435-4,503,453
CFO
-5m
L-3.07%
-1,754,757-1,604,621-3,977,757-4,714,319-6,162,004-3,548,804-987,348-2,087,977-2,916,255-4,402,019-5,289,688-5,127,182
Earnings
May 28, 2025

Profile

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
URL
https://www.ampliatx.com/site/content/
IPO date
Dec 23, 2013
Employees
1
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
4,453
274.34%
1,189
-40.03%
1,983
29.33%
Cost of revenue
8,937
7,475
5,624
Unusual Expense (Income)
NOPBT
(4,484)
(6,286)
(3,640)
NOPBT Margin
Operating Taxes
(4,438)
(1,148)
(1,983)
Tax Rate
NOPAT
(46)
(5,137)
(1,657)
Net income
(4,503)
-27.86%
(6,242)
71.30%
(3,644)
59.75%
Dividends
Dividend yield
Proceeds from repurchase of equity
241
21
13,907
BB yield
0.00%
-0.13%
-65.90%
Debt
Debt current
1,573
2,181
Long-term debt
109
189
2,100
Deferred revenue
Other long-term liabilities
9
4
5
Net debt
(1,704)
(6,886)
(12,508)
Cash flow
Cash from operating activities
(5,127)
(5,290)
(4,402)
CAPEX
(2)
(18)
(14)
Cash from investing activities
(2)
(58)
(27)
Cash from financing activities
(773)
(84)
17,189
FCF
(817)
(4,598)
(2,516)
Balance
Cash
3,385
9,257
14,609
Long term investments
Excess cash
3,163
9,197
14,509
Stockholders' equity
11,418
15,836
21,848
Invested Capital
9,852
8,918
9,444
ROIC
ROCE
EV
Common stock shares outstanding
194,006
193,975
145,549
Price
0.08
-9.41%
0.09
-41.38%
0.15
-44.23%
Market cap
14,938
-9.40%
16,488
-21.88%
21,105
-15.18%
EV
13,234
9,602
8,596
EBITDA
(4,398)
(6,212)
(3,640)
EV/EBITDA
Interest
78
54
Interest/NOPBT